"Designing Growth Strategies is in our DNA"

KRAS Inhibitors Market Size, Share & Industry Analysis, By Drug (Sotorasib, Adagrasib, Divarasib, Olomorasib, RMC-6236, KRAS G12D Inhibitors, and Others), By Disease Indication (Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer, and Others), By Age Group (Pediatric and Adults), By Type (KRAS G12C Inhibitors, KRAS G12D Inhibitors, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail & Drug Store Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

Last Updated: July 03, 2026 | Format: PDF | Report ID: FBI117951

 

Buy Now

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Challenges
    5. Market Trends
  4. Key Insights
    1. Prevalence of Key Diseases, By Key Region/Countries
    2. Overview of Regulatory Scenario, By Key Regions/Countries
    3. New Product Launches, By Key Players
    4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
    5. Pipeline Analysis, By Key Players
  5. Global KRAS Inhibitors Market Analysis, Insights and Forecast, 2021-2034 
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Sotorasib
      2. Adagrasib
      3. Divarasib
      4. Olomorasib
      5. RMC-6236
      6. KRAS G12D Inhibitors
      7. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication               
      1. Non-Small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Adults
      2. Pediatric 
    4. Market Analysis, Insights and Forecast – By Type
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Retail & Drug Store Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – Region
      1.  North America
      2.  Europe
      3.  Asia Pacific
      4.  Latin America
      5.  Middle East & Africa
  6. North America KRAS Inhibitors Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Sotorasib
      2. Adagrasib
      3. Divarasib
      4. Olomorasib
      5. RMC-6236
      6. KRAS G12D Inhibitors
      7. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication               
      1. Non-Small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Adults
      2. Pediatric 
    4. Market Analysis, Insights and Forecast – By Type
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Retail & Drug Store Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada 
  7. Europe KRAS Inhibitors Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Sotorasib
      2. Adagrasib
      3. Divarasib
      4. Olomorasib
      5. RMC-6236
      6. KRAS G12D Inhibitors
      7. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication               
      1. Non-Small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Adults
      2. Pediatric 
    4. Market Analysis, Insights and Forecast – By Type
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Retail & Drug Store Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. U.K.
      2. Germany 
      3. France 
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific KRAS Inhibitors Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Sotorasib
      2. Adagrasib
      3. Divarasib
      4. Olomorasib
      5. RMC-6236
      6. KRAS G12D Inhibitors
      7. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication               
      1. Non-Small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Adults
      2. Pediatric 
    4. Market Analysis, Insights and Forecast – By Type
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Retail & Drug Store Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Southeast Asia
      5. Australia
      6. Rest of Asia Pacific
  9. Latin America KRAS Inhibitors Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Sotorasib
      2. Adagrasib
      3. Divarasib
      4. Olomorasib
      5. RMC-6236
      6. KRAS G12D Inhibitors
      7. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication               
      1. Non-Small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Adults
      2. Pediatric 
    4. Market Analysis, Insights and Forecast – By Type
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Retail & Drug Store Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa KRAS Inhibitors Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Sotorasib
      2. Adagrasib
      3. Divarasib
      4. Olomorasib
      5. RMC-6236
      6. KRAS G12D Inhibitors
      7. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication               
      1. Non-Small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Adults
      2. Pediatric 
    4. Market Analysis, Insights and Forecast – By Type
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Retail & Drug Store Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC 
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis 
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
      1. Amgen Inc.
      2. Bristol Myers Squibb Company
      3. Innovent Biologics, Inc.
      4. InventisBio Co., Ltd.
      5. Jacobio Pharmaceuticals Group Co., Ltd.
      6. Revolution Medicines, Inc.
      7. F. Hoffmann-La Roche Ltd / Genentech, Inc.
      8. Eli Lilly and Company
      9. Astellas Pharma Inc.
      10. Bayer AG 
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Challenges
    5. Market Trends
  4. Key Insights
    1. Prevalence of Key Diseases, By Key Region/Countries
    2. Overview of Regulatory Scenario, By Key Regions/Countries
    3. New Product Launches, By Key Players
    4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
    5. Pipeline Analysis, By Key Players
  5. Global KRAS Inhibitors Market Analysis, Insights and Forecast, 2021-2034 
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Sotorasib
      2. Adagrasib
      3. Divarasib
      4. Olomorasib
      5. RMC-6236
      6. KRAS G12D Inhibitors
      7. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication               
      1. Non-Small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Adults
      2. Pediatric 
    4. Market Analysis, Insights and Forecast – By Type
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Retail & Drug Store Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – Region
      1.  North America
      2.  Europe
      3.  Asia Pacific
      4.  Latin America
      5.  Middle East & Africa
  6. North America KRAS Inhibitors Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Sotorasib
      2. Adagrasib
      3. Divarasib
      4. Olomorasib
      5. RMC-6236
      6. KRAS G12D Inhibitors
      7. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication               
      1. Non-Small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Adults
      2. Pediatric 
    4. Market Analysis, Insights and Forecast – By Type
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Retail & Drug Store Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada 
  7. Europe KRAS Inhibitors Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Sotorasib
      2. Adagrasib
      3. Divarasib
      4. Olomorasib
      5. RMC-6236
      6. KRAS G12D Inhibitors
      7. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication               
      1. Non-Small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Adults
      2. Pediatric 
    4. Market Analysis, Insights and Forecast – By Type
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Retail & Drug Store Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. U.K.
      2. Germany 
      3. France 
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific KRAS Inhibitors Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Sotorasib
      2. Adagrasib
      3. Divarasib
      4. Olomorasib
      5. RMC-6236
      6. KRAS G12D Inhibitors
      7. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication               
      1. Non-Small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Adults
      2. Pediatric 
    4. Market Analysis, Insights and Forecast – By Type
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Retail & Drug Store Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Southeast Asia
      5. Australia
      6. Rest of Asia Pacific
  9. Latin America KRAS Inhibitors Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Sotorasib
      2. Adagrasib
      3. Divarasib
      4. Olomorasib
      5. RMC-6236
      6. KRAS G12D Inhibitors
      7. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication               
      1. Non-Small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Adults
      2. Pediatric 
    4. Market Analysis, Insights and Forecast – By Type
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Retail & Drug Store Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa KRAS Inhibitors Market Analysis, Insights and Forecast, 2021-2034
    1. Market Analysis, Insights and Forecast – By Drug       
      1. Sotorasib
      2. Adagrasib
      3. Divarasib
      4. Olomorasib
      5. RMC-6236
      6. KRAS G12D Inhibitors
      7. Others
    2. Market Analysis, Insights and Forecast – By Disease Indication               
      1. Non-Small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    3. Market Analysis, Insights and Forecast – By Age Group
      1. Adults
      2. Pediatric 
    4. Market Analysis, Insights and Forecast – By Type
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    5. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Retail & Drug Store Pharmacies
      4. Online Pharmacies
    7. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC 
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis 
    1. Global Market Share Analysis (2025)
    2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
      1. Amgen Inc.
      2. Bristol Myers Squibb Company
      3. Innovent Biologics, Inc.
      4. InventisBio Co., Ltd.
      5. Jacobio Pharmaceuticals Group Co., Ltd.
      6. Revolution Medicines, Inc.
      7. F. Hoffmann-La Roche Ltd / Genentech, Inc.
      8. Eli Lilly and Company
      9. Astellas Pharma Inc.
      10. Bayer AG 
Read Less

Figure 1:  Global KRAS Inhibitors Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034

Figure 2:  Global KRAS Inhibitors Market Value Share (%), by Drug, 2025 & 2034

Figure 3:  Global KRAS Inhibitors Market Value Share (%), by Disease Indication, 2025 & 2034

Figure 4:  Global KRAS Inhibitors Market Value Share (%), by Age Group, 2025 & 2034

Figure 5:  Global KRAS Inhibitors Market Value Share (%), by Type, 2025 & 2034

Figure 6:  Global KRAS Inhibitors Market Value Share (%), by Route of Administration, 2025 & 2034

Figure 7:  Global KRAS Inhibitors Market Value Share (%), by Distribution Channel, 2025 & 2034

Figure 8:  Global KRAS Inhibitors Market Value Share (%), by Region, 2025 & 2034

Figure 9:  North America KRAS Inhibitors Market Value (USD million), by Drug, 2025 & 2034

Figure 10:  North America KRAS Inhibitors Market Value Share (%), by Drug, 2025

Figure 11:  North America KRAS Inhibitors Market Value (USD million), by Disease Indication 2025 & 2034

Figure 12:  North America KRAS Inhibitors Market Value Share (%), by Disease Indication 2025

Figure 13:  North America KRAS Inhibitors Market Value (USD million), by Age Group, 2025 & 2034

Figure 14:  North America KRAS Inhibitors Market Value Share (%), by Age Group, 2025

Figure 15:  North America KRAS Inhibitors Market Value (USD million), by Type, 2025 & 2034

Figure 16:  North America KRAS Inhibitors Market Value Share (%), by Type, 2025

Figure 17:  North America KRAS Inhibitors Market Value (USD million), by Route of Administration, 2025 & 2034

Figure 18:  North America KRAS Inhibitors Market Value Share (%), by Route of Administration, 2025

Figure 19:  North America KRAS Inhibitors Market Value (USD million), by Distribution Channel, 2025 & 2034

Figure 20:  North America KRAS Inhibitors Market Value Share (%), by Distribution Channel, 2025

Figure 21:  North America KRAS Inhibitors Market Value (USD million), by Country, 2025 & 2034

Figure 22:  North America KRAS Inhibitors Market Value Share (%), by Country, 2025

Figure 23:  Europe KRAS Inhibitors Market Value (USD million), by Drug, 2025 & 2034

Figure 24:  Europe KRAS Inhibitors Market Value Share (%), by Drug, 2025

Figure 25:  Europe KRAS Inhibitors Market Value (USD million), by Disease Indication 2025 & 2034

Figure 26:  Europe KRAS Inhibitors Market Value Share (%), by Disease Indication 2025

Figure 27:  Europe KRAS Inhibitors Market Value (USD million), by Age Group, 2025 & 2034

Figure 28:  Europe KRAS Inhibitors Market Value Share (%), by Age Group, 2025

Figure 29:  Europe KRAS Inhibitors Market Value (USD million), by Type, 2025 & 2034

Figure 30:  Europe KRAS Inhibitors Market Value Share (%), by Type, 2025

Figure 31:  Europe KRAS Inhibitors Market Value (USD million), by Route of Administration, 2025 & 2034

Figure 32:  Europe KRAS Inhibitors Market Value Share (%), by Route of Administration, 2025

Figure 33:  Europe KRAS Inhibitors Market Value (USD million), by Distribution Channel, 2025 & 2034

Figure 34:  Europe KRAS Inhibitors Market Value Share (%), by Distribution Channel, 2025

Figure 35:  Europe KRAS Inhibitors Market Value (USD million), by Country/ Sub-region, 2025 & 2034

Figure 36:  Europe KRAS Inhibitors Market Value Share (%), by Country/ Sub-region, 2025

Figure 37:  Asia Pacific KRAS Inhibitors Market Value (USD million), by Drug, 2025 & 2034

Figure 38:  Asia Pacific KRAS Inhibitors Market Value Share (%), by Drug, 2025

Figure 39:  Asia Pacific KRAS Inhibitors Market Value (USD million), by Disease Indication 2025 & 2034

Figure 40:  Asia Pacific KRAS Inhibitors Market Value Share (%), by Disease Indication 2025

Figure 41:  Asia Pacific KRAS Inhibitors Market Value (USD million), by Age Group, 2025 & 2034

Figure 42:  Asia Pacific KRAS Inhibitors Market Value Share (%), by Age Group, 2025

Figure 43:  Asia Pacific KRAS Inhibitors Market Value (USD million), by Type, 2025 & 2034

Figure 44:  Asia Pacific KRAS Inhibitors Market Value Share (%), by Type, 2025

Figure 45:  Asia Pacific KRAS Inhibitors Market Value (USD million), by Route of Administration, 2025 & 2034

Figure 46:  Asia Pacific KRAS Inhibitors Market Value Share (%), by Route of Administration, 2025

Figure 47:  Asia Pacific KRAS Inhibitors Market Value (USD million), by Distribution Channel, 2025 & 2034

Figure 48:  Asia Pacific KRAS Inhibitors Market Value Share (%), by Distribution Channel, 2025

Figure 49:  Asia Pacific KRAS Inhibitors Market Value (USD million), by Country/ Sub-region, 2025 & 2034

Figure 50:  Asia Pacific KRAS Inhibitors Market Value Share (%), by Country/ Sub-region, 2025

Figure 51:  Latin America KRAS Inhibitors Market Value (USD million), by Drug, 2025 & 2034

Figure 52:  Latin America KRAS Inhibitors Market Value Share (%), by Drug, 2025

Figure 53:  Latin America KRAS Inhibitors Market Value (USD million), by Disease Indication 2025 & 2034

Figure 54:  Latin America KRAS Inhibitors Market Value Share (%), by Disease Indication 2025

Figure 55:  Latin America KRAS Inhibitors Market Value (USD million), by Age Group, 2025 & 2034

Figure 56:  Latin America KRAS Inhibitors Market Value Share (%), by Age Group, 2025

Figure 57:  Latin America KRAS Inhibitors Market Value (USD million), by Type, 2025 & 2034

Figure 58:  Latin America KRAS Inhibitors Market Value Share (%), by Type, 2025

Figure 59:  Latin America KRAS Inhibitors Market Value (USD million), by Route of Administration, 2025 & 2034

Figure 60:  Latin America KRAS Inhibitors Market Value Share (%), by Route of Administration, 2025

Figure 61:  Latin America KRAS Inhibitors Market Value (USD million), by Distribution Channel, 2025 & 2034

Figure 62:  Latin America KRAS Inhibitors Market Value Share (%), by Distribution Channel, 2025

Figure 63:  Latin America KRAS Inhibitors Market Value (USD million), by Country/ Sub-region, 2025 & 2034

Figure 64:  Latin America KRAS Inhibitors Market Value Share (%), by Country/ Sub-region, 2025

Figure 65:  Middle East & Africa KRAS Inhibitors Market Value (USD million), by Drug, 2025 & 2034

Figure 66:  Middle East & Africa KRAS Inhibitors Market Value Share (%), by Drug, 2025

Figure 67:  Middle East & Africa KRAS Inhibitors Market Value (USD million), by Disease Indication 2025 & 2034

Figure 68:  Middle East & Africa KRAS Inhibitors Market Value Share (%), by Disease Indication 2025

Figure 69:  Middle East & Africa KRAS Inhibitors Market Value (USD million), by Age Group, 2025 & 2034

Figure 70:  Middle East & Africa KRAS Inhibitors Market Value Share (%), by Age Group, 2025

Figure 71:  Middle East & Africa KRAS Inhibitors Market Value (USD million), by Type, 2025 & 2034

Figure 72:  Middle East & Africa KRAS Inhibitors Market Value Share (%), by Type, 2025

Figure 73:  Middle East & Africa KRAS Inhibitors Market Value (USD million), by Route of Administration, 2025 & 2034

Figure 74:  Middle East & Africa KRAS Inhibitors Market Value Share (%), by Route of Administration, 2025

Figure 75:  Middle East & Africa KRAS Inhibitors Market Value (USD million), by Distribution Channel, 2025 & 2034

Figure 76:  Middle East & Africa KRAS Inhibitors Market Value Share (%), by Distribution Channel, 2025

Figure 77:  Middle East & Africa KRAS Inhibitors Market Value (USD million), by Country/ Sub-region, 2025 & 2034

Figure 78:  Middle East & Africa KRAS Inhibitors Market Value Share (%), by Country/ Sub-region, 2025

Figure 79:  Global KRAS Inhibitors Market Share (%), by Company, 2025

Table 1:  Global KRAS Inhibitors Market Revenue (USD million) Forecast, by Drug, 2021–2034

Table 2:  Global KRAS Inhibitors Market Revenue (USD million) Forecast, by Disease Indication 2021–2034

Table 3:  Global KRAS Inhibitors Market Revenue (USD million) Forecast, by Age Group, 2021–2034

Table 4:  Global KRAS Inhibitors Market Revenue (USD million) Forecast, by Type, 2021–2034

Table 5:  Global KRAS Inhibitors Market Revenue (USD million) Forecast, by Route of Administration, 2021–2034

Table 6:  Global KRAS Inhibitors Market Revenue (USD million) Forecast, by Distribution Channel, 2021–2034

Table 7:  Global KRAS Inhibitors Market Revenue (USD million) Forecast, by Region, 2021-2034

Table 8:  North America KRAS Inhibitors Market Revenue (USD million) Forecast, by Drug, 2021–2034

Table 9:  North America KRAS Inhibitors Market Revenue (USD million) Forecast, by Disease Indication 2021–2034

Table 10:  North America KRAS Inhibitors Market Revenue (USD million) Forecast, by Age Group, 2021–2034

Table 11:  North America KRAS Inhibitors Market Revenue (USD million) Forecast, by Type, 2021–2034

Table 12:  North America KRAS Inhibitors Market Revenue (USD million) Forecast, by Route of Administration, 2021–2034

Table 13:  North America KRAS Inhibitors Market Revenue (USD million) Forecast, by Distribution Channel, 2021–2034

Table 14:  North America KRAS Inhibitors Market Revenue (USD million) Forecast, by Country, 2021-2034

Table 15:  Europe KRAS Inhibitors Market Revenue (USD million) Forecast, by Drug, 2021–2034

Table 16:  Europe KRAS Inhibitors Market Revenue (USD million) Forecast, by Disease Indication 2021–2034

Table 17:  Europe KRAS Inhibitors Market Revenue (USD million) Forecast, by Age Group, 2021–2034

Table 18:  Europe KRAS Inhibitors Market Revenue (USD million) Forecast, by Type, 2021–2034

Table 19:  Europe KRAS Inhibitors Market Revenue (USD million) Forecast, by Route of Administration, 2021–2034

Table 20:  Europe KRAS Inhibitors Market Revenue (USD million) Forecast, by Distribution Channel, 2021–2034

Table 21:  Europe KRAS Inhibitors Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034

Table 22:  Asia Pacific KRAS Inhibitors Market Revenue (USD million) Forecast, by Drug, 2021–2034

Table 23:  Asia Pacific KRAS Inhibitors Market Revenue (USD million) Forecast, by Disease Indication 2021–2034

Table 24:  Asia Pacific KRAS Inhibitors Market Revenue (USD million) Forecast, by Age Group, 2021–2034

Table 25:  Asia Pacific KRAS Inhibitors Market Revenue (USD million) Forecast, by Type, 2021–2034

Table 26:  Asia Pacific KRAS Inhibitors Market Revenue (USD million) Forecast, by Route of Administration, 2021–2034

Table 27:  Asia Pacific KRAS Inhibitors Market Revenue (USD million) Forecast, by Distribution Channel, 2021–2034

Table 28:  Asia Pacific KRAS Inhibitors Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034

Table 29:  Latin America KRAS Inhibitors Market Revenue (USD million) Forecast, by Drug, 2021–2034

Table 30:  Latin America KRAS Inhibitors Market Revenue (USD million) Forecast, by Disease Indication 2021–2034

Table 31:  Latin America KRAS Inhibitors Market Revenue (USD million) Forecast, by Age Group, 2021–2034

Table 32:  Latin America KRAS Inhibitors Market Revenue (USD million) Forecast, by Type, 2021–2034

Table 33:  Latin America KRAS Inhibitors Market Revenue (USD million) Forecast, by Route of Administration, 2021–2034

Table 34:  Latin America KRAS Inhibitors Market Revenue (USD million) Forecast, by Distribution Channel, 2021–2034

Table 35:  Latin America KRAS Inhibitors Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034

Table 36:  Middle East & Africa KRAS Inhibitors Market Revenue (USD million) Forecast, by Drug, 2021–2034

Table 37:  Middle East & Africa KRAS Inhibitors Market Revenue (USD million) Forecast, by Disease Indication 2021–2034

Table 38:  Middle East & Africa KRAS Inhibitors Market Revenue (USD million) Forecast, by Age Group, 2021–2034

Table 39:  Middle East & Africa KRAS Inhibitors Market Revenue (USD million) Forecast, by Type, 2021–2034

Table 40:  Middle East & Africa KRAS Inhibitors Market Revenue (USD million) Forecast, by Route of Administration, 2021–2034

Table 41:  Middle East & Africa KRAS Inhibitors Market Revenue (USD million) Forecast, by Distribution Channel, 2021–2034

Table 42:  Middle East & Africa KRAS Inhibitors Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034

KRAS Inhibitors Market
  • 2021-2034
  • 2025
  • 2021-2024
  • 190
Download Free Sample

    man icon
    Mail icon
    Captcha refresh

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Customize Now
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann